BIOS Capital Management, LP
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Oct 2026 | $250,897,987 | Pooled investment vehicles (100%) |
| Jun 2025 to Mar 2026 | $272,018,507 | Pooled investment vehicles (100%) |
| Apr 2025 to May 2025 | $271,080,827 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $277,576,620 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $317,125,502 | Pooled investment vehicles (100%) |
| Apr 2023 | $317,125,502 | Pooled investment vehicles (100%) |
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 100.0%; sector active share 90.6% against the combined 13F book's sector weights.
Over time 7 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
6 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $41,671,189 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RNTX | Rein Therapeutics, Inc. | +1,000,000 | 2,982,375 | $3,101,670 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ACTU |
Actuate Therapeutics, Inc.
Healthcare
|
Held | 10,049,996 | $15,376,493 | 36.90% | |
| IRD |
Opus Genetics, Inc.
Healthcare
|
Held | 3,683,429 | $15,138,893 | 36.33% | |
| CGTX |
Cognition Therapeutics Inc
Healthcare
|
Held | 6,000,000 | $6,899,999 | 16.56% | |
| RNTX |
Rein Therapeutics, Inc.
Healthcare
|
Added | 2,982,375 | $3,101,670 | 7.44% | |
| LTRN |
Lantern Pharma Inc.
Healthcare
|
Reduced | 249,397 | $1,039,985 | 2.50% | |
| INAB |
In8bio, Inc.
Healthcare
|
Reduced | 80,957 | $114,149 | 0.27% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.